Critical Contrast: Oncobiologics (NASDAQ:OTLK) & Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX) and Oncobiologics (NASDAQ:OTLK) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Celldex Therapeutics and Oncobiologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.66%	-47.58%
Oncobiologics	N/A	N/A	-254.82%

Earnings & Valuation

This table compares Celldex Therapeutics and Oncobiologics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$158,000.00	14,846.15	-$258.76 million	($4.30)	-6.95
Oncobiologics	$1.35 million	78.70	-$62.42 million	($0.77)	-0.57

Oncobiologics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Celldex Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Celldex Therapeutics and Oncobiologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1	1	11	0	2.77
Oncobiologics	1	2	2	0	2.20

Celldex Therapeutics currently has a consensus target price of $63.08, suggesting a potential upside of 111.19%. Oncobiologics has a consensus target price of $5.20, suggesting a potential upside of 1,091.57%. Given Oncobiologics’ higher possible upside, analysts plainly believe Oncobiologics is more favorable than Celldex Therapeutics.

Insider and Institutional Ownership

11.2% of Oncobiologics shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Oncobiologics beats Celldex Therapeutics on 7 of the 13 factors compared between the two stocks.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.